Human CXCL17/VCC‑1 Antibody

CXCL17, also known as dendritic cell and monocyte chemokine-like protein (DMC) and VEGF-correlated chemokine-1 (VCC-1), is a secreted molecule with a size and predicted three-dimensional folding pattern similar to that of chemokines CXCL8/IL-8 and CXCL14/BRAK (1, 2). It has no predicted N-glycosylation site. Cleavage of a 23 amino acid (aa) signal sequence yields the mature 96 aa human CXCL17. CXCL17 is constitutively produced by airway and intestinal epithelium (1). It induces the chemotaxis of quiescent, but not LPS-activated peripheral blood monocytes and dendritic cells (1). CXCL17 expression is increased in endothelial cells when they are induced to form tubes in vitro (2). Transgenic overexpression in NIH3T3 cells causes upregulation of proteins such as VEGF and FGF basic, and increases cell growth rate and tumorigenicity (2). CXCL17, plus two other chemokines that play roles in angiogenesis, CXCL1/GRO and CXCL8/IL-8, show a correlated expression pattern with VEGF in primary lung, breast and esophageal tumors (2). CXCL17 is, therefore, suggested to play a role in tumor angiogenesis. Mature human CXCL17 shares 73%, 71% and 64% amino acid sequence identity with bovine, mouse and rat CXCL17, respectively.